Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide vs Investigator's Choice in Relapsed/Refractory DLBCL
NCT01197560Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Sep 2010
- Primary completion
- Jul 2013
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of lenalidomide in diffuse large B-cell lymphoma (DLBCL), sponsored by Celgene Corporation. Started Sep 2010; status: completed.
02
Drugs
lenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT01197560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01197560.